Alzamend Neuro, Inc. Common Stock (ALZN) is a publicly traded Healthcare sector company. As of November 10, 2026, ALZN trades at $1.39 with a market cap of $6.85M and a P/E ratio of -0.55. ALZN moved +0.00% today. Year to date, ALZN is -25.79%; over the trailing twelve months it is -40.25%. Its 52-week range spans $0.84 to $10.17. Analyst consensus is buy with an average price target of $26.00. Rallies surfaces ALZN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alzamend Neuro cuts preferred stock financing to $10 million from $25 million in amended agreement: Alzamend Neuro amended its Series D convertible preferred stock financing with affiliate Ault Lending, reducing it to $10 million from $25 million. The revised agreement requires a $2.5 million second tranche and sets conversion pricing at 80% of the lowest closing bid over five preceding trading days, subject to a $0.2668 floor and $2 cap.
| Metric | Value |
|---|---|
| Price | $1.39 |
| Market Cap | $6.85M |
| P/E Ratio | -0.55 |
| EPS | $-2.63 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.17 |
| 52-Week Low | $0.84 |
| Volume | 15.09K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $8.80M |
| Gross Margin | 0.00% |
1 analysts cover ALZN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $26.00.